- -Integration of existing AI drug development platforms ‘Jewelry’ and ‘Clover’ with expanded AI capabilities
- -Consolidation of biological and chemical informatics big data and AI models
- -Transition to a public cloud environment within the year to significantly accelerate candidate discovery
- -Strengthening AI-driven innovative drug development and open innovation with external research institutions
-
August 2024
JW Pharmaceutical is accelerating the development of innovative drugs through its advanced AI platform.
On the 27th, JW Pharmaceutical announced the official launch of its AI-based integrated drug discovery and development platform, ‘JWave’.
JWave (JW AI-powered Versatile drug Exploration) is JW Pharmaceutical’s proprietary AI-powered drug development platform. It integrates the company’s existing big data-driven drug exploration systems, Jewelry and Clover, while significantly expanding the application scope of its AI models.
Designed for seamless operation throughout the entire drug discovery cycle, JWave allows JW’s New Drug Research Center and C&C New Drug Research Institute to utilize AI technology within a web portal environment. From the rapid identification of active compounds targeting disease-causing proteins to lead optimization and drug candidate discovery, JWave helps reduce costs and shorten research timelines.
The platform harnesses JW’s extensive biological and chemical informatics big data, including over 500 cell lines, organoids, genomic information from various disease animal models, and approximately 40,000 synthetic compounds. It also incorporates more than 20 proprietary AI models to predict and optimize indications, target protein structures, drug design, and ADMET (absorption, distribution, metabolism, excretion, and toxicity).
Notably, JW Pharmaceutical plans to transition JWave from its internal servers to a public cloud environment by the end of this year. This shift is expected to drastically reduce the time required for large-scale genomic data analysis and AI model training, bringing about revolutionary changes to the development timelines of JW’s internal drug discovery projects.
JW Pharmaceutical also intends to leverage JWave to collaborate actively with external biotech companies and research institutions in the pursuit of innovative drug development. Recently, JW joined the ‘K-MELODY’ project, a national initiative led by the Ministry of Health and Welfare and the Ministry of Science and ICT. This collaborative effort aims to develop an ADMET federated learning AI model through partnerships with domestic industry, academia, research, and medical sectors.
Chan-hee Park, Chief Technology Officer (CTO) at JW Pharmaceutical, stated, “JW Pharmaceutical has been at the forefront of building proprietary data science platforms, such as Jewelry and Clover, which have enabled the discovery of over 10 First-in-Class innovative drug candidates. With JWave, we aim to accelerate the development of novel First-in-Class drugs targeting Wnt, Stat, and other innovative mechanisms in oncology, immunology, and regenerative medicine. Additionally, leveraging JWave’s AI capabilities will allow us to advance Best-in-Class and Fast Follower strategies, enabling swift market entry for targeted therapeutics.”